Douglas Rissing/iStock via Getty Images Shares of Citius Pharmaceuticals ( NASDAQ: CTXR ) rose on Tuesday after the critical care product developer said its pivotal Phase 3 clinical trial for its Mino-Lok antibiotic lock solution succeeded. Based on topline results, Citius ( CTXR ) said Mino Lok, designed as a non-invasive alternative to catheter removal and replacement, led to a statistically significant improvement in the time to a catheter failure event, meeting the trial's primary goal. The study enrolled patients from the U.
S. and India who had received an indwelling central venous catheter before the start of a bloodstream infection. They received Mino-Lok, or standard of care (SOC) anti-infective lock solutions in addition to SOC antibiotics.
The Cranford, New Jersey-headquartered pharmaceutical company intends to meet with the FDA to decide on a potential registration path for Mino Lok, which it says offers an alternative to the current SOC of catheter removal and replacement. More on Citius Pharmaceuticals Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citius Pharmaceuticals.